Wolf Popper LLP Announces Investigation on Behalf of CVRx, Inc. Investors
CVRx, Inc. (CVRX)
Company Research
Source: GlobeNewswire
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx”) common stock (NASDAQ: CVRX). CVRx is a medical device company. CVRx’s principal product is Barostim, which acts like a pacemaker. On April 30, 2024, CVRx announced weak first quarter results, which the company blamed on a disruption in the salesforce caused by the retirement of the prior Chief Executive Officer. During the earnings call that day, and in subsequent earnings calls, CVRx management said issues with the salesforce had been stabilized. For example, during CVRx’s third quarter 2024 earnings call conducted on October 29, 2024, CVRx’s President and Chief Executive Officer, Kevin Hykes said “Our strengthened leadership team and stabilized sales force have been instrumental in driving our market development priorities and advancing the adoption of Barostim therapy.” After the market closed on April 7, 2025, CVRx announced weak prelimi
Show less
Read more
Impact Snapshot
Event Time:
CVRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVRX alerts
High impacting CVRx, Inc. news events
Weekly update
A roundup of the hottest topics
CVRX
News
- CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 GuidanceGlobeNewswire
- CVRx Announces Implementation of New Category I CPT Codes for Barostim TherapyGlobeNewswire
- CVRx (NASDAQ:CVRX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- CVRx to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- CVRx to Participate at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
CVRX
Earnings
- 11/5/25 - Beat
CVRX
Sec Filings
- 1/12/26 - Form SCHEDULE
- 1/12/26 - Form 8-K
- 1/12/26 - Form 424B5
- CVRX's page on the SEC website